ONCAlert | Upfront Therapy for mRCC
Videos  >  

Rationale for Locally Aggressive Treatment of Pancreatic Cancer

Amol K. Narang, MD
Published Online:2:40 PM, Mon November 12, 2018


Amol K. Narang, MD, assistant professor of radiation oncology and molecular radiation sciences, John Hopkins Sidney Kimmel Comprehensive Cancer Center, discusses the improvement in systemic therapy for the treatment of pancreatic cancer in recent years. He says that the combination of various chemotherapies are showing potential in a number of trials.

In 2 landmark studies, the combination of FOLFIRINOX [folinic acid, fluorouracil (5-FU), irinotecan, and oxaliplatin] with gemcitabine and paclitaxel has shown significant improvement over the standard of care, gemcitabine alone.

These combinations are leading to better control, which has caused an increased interest in treating pancreatic cancer with more locally aggressive treatments.
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.